177 related articles for article (PubMed ID: 14983226)
1. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
2. Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells.
Lim YT; Sugiura Y; Laug WE; Sun B; Garcia A; DeClerck YA
J Cell Physiol; 1996 May; 167(2):333-40. PubMed ID: 8613475
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolytic activity during orthotopic liver transplantation with and without aprotinin.
Segal HC; Hunt BJ; Cottam S; Downing A; Beard C; Francis JL; Potter D; Tan KC
Transplantation; 1994 Dec; 58(12):1356-60. PubMed ID: 7528949
[TBL] [Abstract][Full Text] [Related]
4. Hemostasis and blood requirements in orthotopic liver transplantation with and without high-dose aprotinin.
Llamas P; Cabrera R; Gómez-Arnau J; Fernández MN
Haematologica; 1998 Apr; 83(4):338-46. PubMed ID: 9592984
[TBL] [Abstract][Full Text] [Related]
5. Evolution of urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA) in orthotopic liver transplantation (OLT).
Himmelreich G; Dooijewaard G; Breinl P; Bechstein WO; Neuhaus P; Kluft C; Riess H
Thromb Haemost; 1993 Jan; 69(1):56-9. PubMed ID: 8446939
[TBL] [Abstract][Full Text] [Related]
6. Changes in the contact system during orthotopic liver transplantation with and without aprotinin.
Segal HC; Hunt BJ; Cottam S; Beard C; Francis JL; Potter D; Tan KC
Transplantation; 1995 Feb; 59(3):366-70. PubMed ID: 7532878
[TBL] [Abstract][Full Text] [Related]
7. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line.
Lombard MA; Wallace TL; Kubicek MF; Petzold GL; Mitchell MA; Hendges SK; Wilks JW
Cancer Res; 1998 Sep; 58(17):4001-7. PubMed ID: 9731514
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo.
Della Porta P; Soeltl R; Krell HW; Collins K; O'Donoghue M; Schmitt M; Krüger A
Anticancer Res; 1999; 19(5B):3809-16. PubMed ID: 10628317
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of tissue inhibitor of metalloproteinase-1 and loss of correlation with matrix metalloproteinase-9 by macrophages in asthma.
Mautino G; Henriquet C; Gougat C; Le Cam A; Dayer JM; Bousquet J; Capony F
Lab Invest; 1999 Jan; 79(1):39-47. PubMed ID: 9952109
[TBL] [Abstract][Full Text] [Related]
10. Transhepatic metabolism of TNF-alpha, IL-6, and endotoxin in the early hepatic reperfusion period after human liver transplantation.
Steininger R; Roth E; Függer R; Winkler S; Längle F; Grünberger T; Götzinger P; Sautner T; Mühlbacher F
Transplantation; 1994 Jul; 58(2):179-83. PubMed ID: 8042235
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 change predictably in rheumatoid arthritis patients who have begun activity after a night of bed rest.
Manicourt DH; Poilvache P; Nzeusseu A; van Egeren A; Devogelaer JP; Lenz ME; Thonar EJ
Arthritis Rheum; 1999 Sep; 42(9):1861-9. PubMed ID: 10513800
[TBL] [Abstract][Full Text] [Related]
12. Transfusion requirements are correlated with the degree of proteolysis of von Willebrand factor during orthotopic liver transplantation.
Lattuada A; Mannucci PM; Chen C; Legnani C; Palareti G
Thromb Haemost; 1997 Aug; 78(2):813-9. PubMed ID: 9268177
[TBL] [Abstract][Full Text] [Related]
13. Increased urokinase-type plasminogen activator (u-PA) levels in graft liver perfusate and decreased single chain u-PA activation with higher levels of aprotinin.
Himmelreich G; Dooijewaard G; Neuhaus P; Kluft C; Bechstein WO; Riess H
Thromb Haemost; 1994 Jan; 71(1):12-4. PubMed ID: 7513093
[TBL] [Abstract][Full Text] [Related]
14. Changes in urokinase-type plasminogen activator in orthotopic liver transplantation.
Himmelreich G; Dooijewaard G; Breinl P; Bechstein WO; Blumhardt G; Kluft C; Riess H
Semin Thromb Hemost; 1993; 19(3):311-4. PubMed ID: 7689759
[TBL] [Abstract][Full Text] [Related]
15. Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the bisphosphonate alendronate.
Farina AR; Tacconelli A; Teti A; Gulino A; Mackay AR
Cancer Res; 1998 Jul; 58(14):2957-60. PubMed ID: 9679953
[TBL] [Abstract][Full Text] [Related]
16. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C.
Lichtinghagen R; Huegel O; Seifert T; Haberkorn CI; Michels D; Flemming P; Bahr M; Boeker KH
Clin Chem; 2000 Feb; 46(2):183-92. PubMed ID: 10657374
[TBL] [Abstract][Full Text] [Related]
17. Plasma thrombomodulin in orthotopic liver transplantation.
Boutiere B; Arnoux D; Boffa MC; Samson D; Le Treut YP; Sampol J
Transplantation; 1994 Dec; 58(12):1352-5. PubMed ID: 7809928
[TBL] [Abstract][Full Text] [Related]
18. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin.
Ray MJ; Marsh NA
Thromb Haemost; 1997 Sep; 78(3):1021-6. PubMed ID: 9308747
[TBL] [Abstract][Full Text] [Related]
19. Production and activation of matrix metalloprotease-9 (MMP-9) by HL-60 promyelocytic leukemia cells.
Devy L; Noël A; Baramova E; Bajou K; Trentesaux C; Jardillier JC; Foidart JM; Jeannesson P
Biochem Biophys Res Commun; 1997 Sep; 238(3):842-6. PubMed ID: 9325178
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis.
Walsh KM; Timms P; Campbell S; MacSween RN; Morris AJ
Dig Dis Sci; 1999 Mar; 44(3):624-30. PubMed ID: 10080160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
